Oncolys BioPharma, Inc.(JP:4588)
Â¥7,620.00-460.00 (-5.69%)
JP:4588
Oncolys BioPharma, Inc. financials statements
Â¥7,620.00
At close:-460.00 (-5.69%)
Want to see JP:4588 full AI Analyst Report?
Oncolys BioPharma, Inc. (4588) Ratios
1 Followers
Oncolys BioPharma, Inc. Ratios
JP:4588's free cash flow for Q4 2025 was ¥0.00. For the 2025 fiscal year, JP:4588's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.55 | 12.28 | 5.17 | 8.11 | 9.76 |
| Quick Ratio | 9.54 | 12.26 | 5.15 | 8.04 | 9.73 |
| Cash Ratio | 7.81 | 9.55 | 3.40 | 4.56 | 7.46 |
| Solvency Ratio | -3.70 | -3.77 | -3.42 | -2.33 | -2.31 |
| Operating Cash Flow Ratio | -4.12 | -8.00 | -3.53 | -5.34 | -4.05 |
| Short-Term Operating Cash Flow Coverage | -7.97 | -15.81 | -10.46 | -7.54 | -7.29 |
| Net Current Asset Value | ¥ 3.94B | ¥ 2.65B | ¥ 1.39B | ¥ 2.12B | ¥ 3.50B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.10 | 0.15 | 0.15 | 0.12 |
| Debt-to-Equity Ratio | 0.08 | 0.12 | 0.21 | 0.18 | 0.14 |
| Debt-to-Capital Ratio | 0.07 | 0.11 | 0.18 | 0.15 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.06 | 0.10 | 0.07 | 0.07 |
| Financial Leverage Ratio | 1.14 | 1.16 | 1.38 | 1.23 | 1.19 |
| Debt Service Coverage Ratio | -8.25 | -12.69 | -14.71 | -4.94 | -6.60 |
| Interest Coverage Ratio | -386.72 | -365.76 | -535.81 | -305.32 | -348.90 |
| Debt to Market Cap | 0.01 | 0.03 | 0.03 | 0.04 | 0.06 |
| Interest Debt Per Share | 12.64 | 15.08 | 17.91 | 22.95 | 30.01 |
| Net Debt to EBITDA | 1.64 | 1.25 | 0.50 | 0.94 | 1.69 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.15% | 100.00% | 48.55% | 34.67% | 30.94% |
| EBIT Margin | -7177.12% | -5341.63% | -3064.78% | -116.99% | -250.20% |
| EBITDA Margin | -7176.27% | -5339.03% | -3061.15% | -116.90% | -249.19% |
| Operating Profit Margin | -7090.55% | -5357.52% | -3061.62% | -123.39% | -226.39% |
| Pretax Profit Margin | -7195.46% | -5356.28% | -3070.49% | -117.40% | -250.85% |
| Net Profit Margin | -7209.59% | -5368.27% | -3075.14% | -117.70% | -251.43% |
| Continuous Operations Profit Margin | -7209.58% | -5368.27% | -3075.14% | -117.70% | -251.43% |
| Net Income Per EBT | 100.20% | 100.22% | 100.15% | 100.26% | 100.23% |
| EBT Per EBIT | 101.48% | 99.98% | 100.29% | 95.14% | 110.80% |
| Return on Assets (ROA) | -45.17% | -52.67% | -95.00% | -43.34% | -37.64% |
| Return on Equity (ROE) | -51.45% | -61.22% | -131.50% | -53.21% | -44.95% |
| Return on Capital Employed (ROCE) | -49.55% | -57.07% | -116.12% | -51.71% | -37.67% |
| Return on Invested Capital (ROIC) | -46.76% | -54.51% | -107.38% | -47.04% | -35.45% |
| Return on Tangible Assets | -45.17% | -52.67% | -95.00% | -43.34% | -37.64% |
| Earnings Yield | -5.78% | -14.90% | -19.21% | -12.58% | -18.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.08 | 0.31 | 0.62 | 3.07 | 1.82 |
| Payables Turnover | 0.00 | 0.00 | 0.17 | 10.48 | 4.18 |
| Inventory Turnover | 0.06 | 0.18 | 6.07 | 26.30 | 38.07 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 46.16 | 30.28 |
| Asset Turnover | 0.01 | 0.01 | 0.03 | 0.37 | 0.15 |
| Working Capital Turnover Ratio | 0.01 | 0.01 | 0.03 | 0.32 | 0.22 |
| Cash Conversion Cycle | 10681.94 | 3241.39 | -1526.76 | 98.10 | 122.24 |
| Days of Sales Outstanding | 4775.57 | 1191.12 | 589.12 | 119.05 | 200.05 |
| Days of Inventory Outstanding | 5906.36 | 2050.27 | 60.12 | 13.88 | 9.59 |
| Days of Payables Outstanding | 0.00 | 0.00 | 2176.00 | 34.83 | 87.40 |
| Operating Cycle | 10681.94 | 3241.39 | 649.24 | 132.93 | 209.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -75.44 | -92.53 | -75.12 | -99.10 | -102.97 |
| Free Cash Flow Per Share | -75.56 | -92.69 | -75.44 | -99.18 | -103.06 |
| Dividend Paid and CapEx Coverage Ratio | -643.95 | -574.05 | -235.13 | -1264.46 | -1212.13 |
| Capital Expenditure Coverage Ratio | -643.95 | -574.05 | -235.13 | -1264.46 | -1212.13 |
| Operating Cash Flow Coverage Ratio | -6.06 | -6.22 | -4.24 | -4.36 | -3.46 |
| Operating Cash Flow to Sales Ratio | -67.99 | -64.37 | -21.21 | -1.76 | -2.71 |
| Free Cash Flow Yield | -5.46% | -17.89% | -13.30% | -18.82% | -19.52% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -17.30 | -6.71 | -5.21 | -7.95 | -5.53 |
| Price-to-Sales (P/S) Ratio | 1247.26 | 360.33 | 160.08 | 9.35 | 13.90 |
| Price-to-Book (P/B) Ratio | 8.90 | 4.11 | 6.85 | 4.23 | 2.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.32 | -5.59 | -7.52 | -5.31 | -5.12 |
| Price-to-Operating Cash Flow Ratio | -18.34 | -5.60 | -7.55 | -5.32 | -5.13 |
| Price-to-Earnings Growth (PEG) Ratio | -4.72 | 0.23 | -0.08 | 0.26 | 0.16 |
| Enterprise Value Multiple | -15.74 | -5.50 | -4.73 | -7.06 | -3.89 |
| Enterprise Value | 32.25B | 9.22B | 9.12B | 8.06B | 6.23B |
| EV to EBITDA | -15.74 | -5.50 | -4.73 | -7.06 | -3.89 |
| EV to Sales | 1129.74 | 293.85 | 144.65 | 8.26 | 9.69 |
| EV to Free Cash Flow | -16.59 | -4.56 | -6.79 | -4.69 | -3.57 |
| EV to Operating Cash Flow | -16.62 | -4.57 | -6.82 | -4.69 | -3.57 |
| Tangible Book Value Per Share | 155.49 | 126.07 | 82.83 | 124.62 | 212.47 |
| Shareholders’ Equity Per Share | 155.49 | 126.07 | 82.83 | 124.62 | 212.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 1.11 | 1.44 | 3.54 | 56.34 | 37.98 |
| Net Income Per Share | -80.00 | -77.17 | -108.92 | -66.31 | -95.50 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 51.51 | 34.70 | 21.45 | 0.97 | 1.28 |
| SG&A to Revenue | 20.39 | 54.77 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.62 | 0.16 | 0.06 | 0.33 |
| Income Quality | 0.94 | 1.20 | 0.69 | 1.50 | 1.08 |
Currency in JPY

